Back to Search Start Over

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Authors :
Kissling E
Hooiveld M
Sandonis Martín V
Martínez-Baz I
William N
Vilcu AM
Mazagatos C
Domegan L
de Lusignan S
Meijer A
Machado A
Brytting M
Casado I
Murray JK
Belhillil S
Larrauri A
O'Donnell J
Tsang R
de Lange M
Rodrigues AP
Riess M
Castilla J
Hamilton M
Falchi A
Pozo F
Dunford L
Cogdale J
Jansen T
Guiomar R
Enkirch T
Burgui C
Sigerson D
Blanchon T
Martínez Ochoa EM
Connell J
Ellis J
van Gageldonk-Lafeber R
Kislaya I
Rose AM
Valenciano M
Source :
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2021 Jul; Vol. 26 (29).
Publication Year :
2021

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Details

Language :
English
ISSN :
1560-7917
Volume :
26
Issue :
29
Database :
MEDLINE
Journal :
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Publication Type :
Academic Journal
Accession number :
34296676
Full Text :
https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670